Surufatinib Combined With Standard chemotherapy
Phase 2Small molecule
Surufatinib Combined With Standard chemotherapy is one of 6 small molecule programs targeting Pulmonary Neuroendocrine Tumor. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Pulmonary Neuroendocrine Tumor
#DrugCompanyPhaseTrials
1Afinitor
NovartisApproved
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Cabometyx
Bristol-Myers SquibbPhase 2
Surufatinib
HHutchison Medipharma Limited
Phase 2
RAD001
NovartisPhase 1
Surufatinib Combined With Standard chemotherapy
SShanghai Chest Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai Chest Hospital